您当前所在的位置:首页 > 产品中心 > 产品信息
Oxybutynin_分子结构_CAS_5633-20-5)
点击图片或这里关闭

Oxybutynin

产品号 DB01062 公司名称 DrugBank
CAS号 5633-20-5 公司网站 http://www.ualberta.ca/
分子式 C22H31NO3 电 话 (780) 492-3111
分子量 357.48644 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 933

产品价格信息

请登录

产品别名

标题
Oxybutynin
IUPAC标准名
4-(diethylamino)but-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate
IUPAC传统名
oxybutynin
商标名
Ditropan
Ditropan Xl
Oxytrol
别名
oxybutynin topical gel
Oxybutynine [INN-French]
Oxybutynin Base
oxybutynin
Oxybutinin
Oxibutinina [INN-Spanish]
Oxibutyninum
Oxybutynin Chloride
Oxybutynin Hydrochloride
Oxybutyninum [INN-Latin]
transdermal patch

产品登记号

CAS号 5633-20-5
PubChem SID 46508005
PubChem CID 4634

产品性质

疏水性(logP) 4.3

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved; investigational
Description Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties, including frequent urination and inability to control urination, by decreasing muscle spasms of the bladder. It competitively antagonizes the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor.
Indication For the treatment of overactive bladder.
Pharmacology Oxybutynin is an antispasmodic, anticholinergic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin relaxes bladder smooth muscle. Oxybutynin exhibits only one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to ten times the antispasmodic activity. Antimuscarinic activity resides predominantly in the R-isomer.
Toxicity LD50=1220 mg/kg (Orally in rats, Goldenthal)
Affected Organisms
Humans and other mammals
Biotransformation Hepatic, primarily by CYP3A4
Absorption Rapidly absorbed from gastrointestinal tract.
Half Life 12.4-13.2 hours
Protein Binding 91%-93%
Elimination Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. Oxybutynin is extensively metabolized by the liver, with less than 0.1% of the administered dose excreted unchanged in the urine.
Also, less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin.
Distribution * 193 L
References
Tupker RA, Harmsze AM, Deneer VH: Oxybutynin therapy for generalized hyperhidrosis. Arch Dermatol. 2006 Aug;142(8):1065-6. [Pubmed]
Mijnhout GS, Kloosterman H, Simsek S, Strack van Schijndel RJ, Netelenbos JC: Oxybutynin: dry days for patients with hyperhidrosis. Neth J Med. 2006 Oct;64(9):326-8. [Pubmed]
Schollhammer M, Misery L: Treatment of hyperhidrosis with oxybutynin. Arch Dermatol. 2007 Apr;143(4):544-5. [Pubmed]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

参考文献

  • Tupker RA, Harmsze AM, Deneer VH: Oxybutynin therapy for generalized hyperhidrosis. Arch Dermatol. 2006 Aug;142(8):1065-6. Pubmed
  • Mijnhout GS, Kloosterman H, Simsek S, Strack van Schijndel RJ, Netelenbos JC: Oxybutynin: dry days for patients with hyperhidrosis. Neth J Med. 2006 Oct;64(9):326-8. Pubmed
  • Schollhammer M, Misery L: Treatment of hyperhidrosis with oxybutynin. Arch Dermatol. 2007 Apr;143(4):544-5. Pubmed